Voglibose

Voglibose
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
IUPAC name
  • (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H21NO7
Molar mass267.278 g·mol−1
3D model (JSmol)
SMILES
  • OC[C@@]1(O)C[C@H](NC(CO)CO)[C@H](O)[C@@H](O)[C@@H]1O
InChI
  • InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1 checkY
  • Key:FZNCGRZWXLXZSZ-CIQUZCHMSA-N checkY
  (verify)

Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus.[1] Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Vogilbose was discovered in 1981, and was first launched in Japan in 1994,[2] under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.[3]

Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.[2]

There are three major drugs which belong to this class, acarbose, miglitol and voglibose,[2] of which voglibose is the newest.

References

  1. ↑ Chen X, Zheng Y, Shen Y (2006). "Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors". Current Medicinal Chemistry. 13 (1): 109–16. doi:10.2174/092986706789803035. PMID 16457643.
  2. 1 2 3 Dabhi AS, Bhatt NR, Shah MJ (December 2013). "Voglibose: an alpha glucosidase inhibitor". Journal of Clinical and Diagnostic Research. 7 (12): 3023–7. doi:10.7860/JCDR/2013/6373.3838. PMC 3919386. PMID 24551718.
  3. ↑ "Voglibose". AdisInsight. Springer Nature Switzerland AG.

Further reading

  • Greenstein B (2004). Clinical Pharmacology for nurses (17th ed.). Elsevier Limited, Churchill Livingstone.
  • Andrew L. Wilson (1997). Ila V. Mehra (ed.). Managing the Patient with Type II Diabetes. Aspen Publishers. pp. 62–63. ISBN 978-0-8342-1018-9.{{cite book}}: CS1 maint: uses authors parameter (link)
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.